Drug Designing: Open Access
Open Access
ISSN: 2169-0138
ISSN: 2169-0138
The occurrence of the coronavirus disease 2019 (COVID-19) is formally recognized as a severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) and characterized as a universal public health problem. Coronavirus disease 2019 (COVID-19) infects the lower respiratory system to cause viral pneumonia, and also leads to multiple organ damage including kidney, liver and etc. The coronavirus disease 2019 is spread and transmits through human-to-human by means of droplets, feco-oral, and direct contact. Applying the protective mechanism is the only option to control COVID-19 infection due to the absence of approved antiviral treatment or vaccine for the prevention and treatment of COVID-19. Therefore, developing a safe and effective therapeutic agent is necessary to overcome the overcoming potential impact of coronavirus disease in 2019 in the world. This review focus on the current clinical trials under investigation on the potential drug candidates for the treatment of coronavirus disease 2019 to support the scientific community for further research and development efforts to discover safe and effective therapeutic and preventive agents for COVID-19. Drug under investigation especially remdesivir had benefits to reduce duration of symptom onset from clinical manifestation and reduce duration of hospitalization in some patients. Based on clinical trial, the known and potential benefits of remdesivir outweigh the known and potential risks of the drug for the treatment of severe COVID-19 in hospitalized patients depends on data obtained from clinical trial.
Published Date: 2020-08-06; Received Date: 2020-07-15